Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research in the last decade. It may even surpass PCR as a top technology. RNA interference allows scientists to silence the expression or effect of a gene being studied. Known simply as RNAi, this field has rapidly emerged as a fast growing new market. Much like the go-go times of 1999, VC investments in 2003-2005 have produced a growing new crop of interesting RNAi companies.

This report assesses this emerging commercial market and maps the players on the market landscape. The initial companies produced reagents and kits for the biological research reagents market to support basic and applied research in academia, government and industry. A number of companies decided to take the long road to develop therapeutics. Others have developed drug delivery approaches for emerging RNAi therapeutics.

Some companies have decided to focus on offering RNAi based target validation products or services for drug discovery or to companies like big pharmas or biotech drug discovery firms. Other companies are trying other approaches such as making libraries or databases of the results of their experiments. This content or related service may help researchers see the big picture faster at lower cost.

This research report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. Detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like. This report includes 21 company profiles that provide the reader a snapshot of the companiesÕ focus or activities.

Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research in the last decade. It may even surpass PCR as a top technology. RNA interference allows scientists to silence the expression or effect of a gene being studied. Known simply as RNAi, this field has rapidly emerged as a fast growing new market. Much like the go-go times of 1999, VC investments in 2003-2005 have produced a growing new crop of interesting RNAi companies.

This report assesses this emerging commercial market and maps the players on the market landscape. The initial companies produced reagents and kits for the biological research reagents market to support basic and applied research in academia, government and industry. A number of companies decided to take the long road to develop therapeutics. Others have developed drug delivery approaches for emerging RNAi therapeutics.

Some companies have decided to focus on offering RNAi based target validation products or services for drug discovery or to companies like big pharmas or biotech drug discovery firms. Other companies are trying other approaches such as making libraries or databases of the results of their experiments. This content or related service may help researchers see the big picture faster at lower cost.

This research report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. Detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like. This report includes 21 company profiles that provide the reader a snapshot of the companiesÕ focus or activities.